News | Lung Imaging | January 23, 2023

Lack of adherence is linked to greater mortality rates 

Summary of imaging findings from the SEER-Medicare linked database for patients with non-small cell lung cancer prior to receiving subsequent radiation therapy. Image created by Emily Sterbis, MD, Interventional Radiology Resident at the University of Colorado

Summary of imaging findings from the SEER-Medicare linked database for patients with non-small cell lung cancer prior to receiving subsequent radiation therapy. Image created by Emily Sterbis, MD, Interventional Radiology Resident at the University of Colorado 


January 23, 2023 — A study published in the January issue of The Journal of Nuclear Medicine reports that approximately one out of every two Medicare patients with non-small cell lung cancer (NSCLC) does not receive the appropriate imaging prior to receiving radiation therapy. Significant improvement in overall and cancer-specific survival rates was found in patients who had FDG PET/CT imaging—which is recommended by the National Comprehensive Cancer Network (NCCN)—compared to those who underwent CT imaging alone. 

Lung cancer is the leading cause of cancer-related deaths in the United States. Imaging NSCLC with FDG PET/CT offers high sensitivity for staging and has been shown to change treatment decisions for up to 72 percent of patients with the disease. As such, NCCN guidelines recommend that all NSCLC patients with evidence of recurrence receive FDG PET/CT to evaluate for metastatic disease.
To assess the adherence to these guidelines, researchers conducted a retrospective study of patients with NSCLC in the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database. More than 5,000 NSCLC patients requiring radiation therapy were included in the study and were split into two cohorts: those who received CT imaging only and those who received FDG PET/CT imaging. Next, researchers analyzed the overall and cancer-specific survival rates of these two groups. 

The analysis found that 56.3 percent of patients underwent FDG PET/CT prior to radiation therapy, while 43.6 percent had imaging with CT alone. When survival of the patients was compared over a three-year follow-up period, patients who received CT only had statistically significant decreased overall and cancer-specific survival as compared to those who received FDG PET/CT imaging. 

“This research shows a clear lack of adherence to guidelines and raises important questions as to why. We believe these findings are the tip of the iceberg for guideline nonadherence. More work needs to be done in order to better understand the scope of the issue, with future work focused on interventions which ensure guideline adherence,” noted Rustain Morgan, MD, MS, nuclear radiologist at the University of Colorado in Aurora, Colorado.   

For more information: www.snmmi.org


Related Content

News | Radiopharmaceuticals and Tracers

April 5, 2024 — RLS Radiopharmacies, America’s only Joint Commission-accredited radiopharmacy network, today announced ...

Time April 05, 2024
arrow
News | Molecular Imaging

March 29, 2024 — Magnetic resonance imaging (MRI) is a cornerstone in the landscape of medical diagnostics, celebrated ...

Time March 29, 2024
arrow
News | Coronavirus (COVID-19)

March 21, 2024 — Artificial intelligence can spot COVID-19 in lung ultrasound images much like facial recognition ...

Time March 21, 2024
arrow
News | Coronavirus (COVID-19)

March 20, 2024 — SARS-CoV-2, the virus that causes COVID-19, can damage the heart even without directly infecting the ...

Time March 20, 2024
arrow
News | Artificial Intelligence

March 6, 2024 — Body Vision Medical, a leader in AI-driven, intraoperative imaging, announced the successful validation ...

Time March 06, 2024
arrow
News | Artificial Intelligence

February 29, 2024 — AIxSCAN, Inc., a Sunnyvale, CA-based developer of a next generation artificial intelligence (AI) ...

Time February 29, 2024
arrow
News | Artificial Intelligence

February 26, 2024 — DeepHealth, Inc., one of the leading providers in healthcare radiology informatics, has today ...

Time February 26, 2024
arrow
News | Radiopharmaceuticals and Tracers

February 21, 2024 — Blue Earth Therapeutics, a Bracco company and emerging leader in the development of innovative next ...

Time February 21, 2024
arrow
News | Radiopharmaceuticals and Tracers

February 14, 2024 — PanTera, the Belgian joint venture created by IBA and SCK CEN to secure large-scale production of ...

Time February 14, 2024
arrow
Subscribe Now